Medpace Holdings Faces Class Action Lawsuit Reminder
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 42 minutes ago
0mins
Source: Globenewswire
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Medpace Holdings (NASDAQ:MEDP) for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between April 22, 2025, and February 9, 2026.
- False Statements Allegation: The complaint alleges that Medpace made false and misleading statements during the class period, artificially inflating its share price, which led to investor losses when the truth was revealed, indicating significant misrepresentation by the company.
- Investor Action Call: Affected investors are encouraged to contact the Schall Law Firm before June 5, 2026, to participate in the lawsuit and seek compensation for their losses, highlighting the legal risks that could impact shareholder value.
- Law Firm Background: The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally, demonstrating its expertise and influence in protecting investor rights.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MEDP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MEDP
Wall Street analysts forecast MEDP stock price to rise
7 Analyst Rating
1 Buy
4 Hold
2 Sell
Hold
Current: 430.100
Low
462.00
Averages
569.17
High
660.00
Current: 430.100
Low
462.00
Averages
569.17
High
660.00
About MEDP
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Medpace Holdings Faces Class Action Lawsuit Reminder
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Medpace Holdings (NASDAQ:MEDP) for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between April 22, 2025, and February 9, 2026.
- False Statements Allegation: The complaint alleges that Medpace made false and misleading statements during the class period, artificially inflating its share price, which led to investor losses when the truth was revealed, indicating significant misrepresentation by the company.
- Investor Action Call: Affected investors are encouraged to contact the Schall Law Firm before June 5, 2026, to participate in the lawsuit and seek compensation for their losses, highlighting the legal risks that could impact shareholder value.
- Law Firm Background: The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally, demonstrating its expertise and influence in protecting investor rights.
See More
Medpace Faces Class Action for Securities Fraud
- Lawsuit Background: Bleichmar Fonti & Auld LLP has filed a class action against Medpace Holdings Inc. and its executives for securities fraud, leading to significant stock declines and raising serious concerns about the company's financial transparency among investors.
- Stock Price Plunge: On February 9, 2026, Medpace reported a book-to-bill ratio drop to 1.04 due to increased cancellations, causing its stock price to plummet from $530.35 to $446.05, a 15.9% decline, reflecting market disappointment with its performance.
- Ongoing Decline: BFA is investigating reports of rising cancellation rates and a further decline in the book-to-bill ratio, which fell to 0.88 for 1Q 26, indicating increasing operational pressures that could impact future financing capabilities.
- Executive Changes: The resignation of Medpace President Jesse Geiger adds to the uncertainty surrounding the company's governance and future prospects, potentially leading to further erosion of investor confidence.
See More
Medpace Holdings Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Medpace Holdings, aiming to recover damages for investors who purchased securities between April 22, 2025, and February 9, 2026, highlighting serious concerns over the company's financial transparency.
- False Statement Allegations: The complaint alleges that Medpace repeatedly overstated its book-to-bill ratio of 1.15 during earnings calls, despite contrary internal information, which not only harmed investor interests but could also impact the company's future market credibility.
- Investor Participation Opportunity: Affected investors have until June 5, 2026, to request to be appointed as lead plaintiff, indicating the company's commitment to investor rights while providing a legal avenue for potential compensation.
- Legal Fee Arrangement: Bronstein, Gewirtz & Grossman, LLC offers legal services on a contingency fee basis, meaning fees are only collected upon successful recovery, thereby reducing the financial burden on investors and encouraging broader participation in the lawsuit.
See More
Medpace Holdings Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Medpace Holdings (NASDAQ:MEDP) for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between April 22, 2025, and February 9, 2026, with a deadline for participation set for June 5, 2026.
- False Statements Allegation: The complaint alleges that Medpace made false and misleading statements during the class period, artificially inflating its share price, which resulted in investor losses once the truth about the company's performance was revealed, indicating significant misrepresentation in public disclosures.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations for affected investors, encouraging them to discuss their rights, highlighting the firm's specialization in securities class action lawsuits and shareholder rights litigation aimed at helping investors recover losses.
- Lawsuit Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, underscoring the importance of taking action to protect their rights and interests.
See More
Medpace Faces Class Action Lawsuit Allegations
- Class Action Initiation: Robbins Geller law firm announces that investors who purchased Medpace Holdings Inc. stock between April 22, 2025, and February 9, 2026, can seek lead plaintiff status by June 8, 2026, indicating strong investor concern over the company's financial transparency.
- Financial Misrepresentation Allegations: The lawsuit alleges that Medpace and its executives made false or misleading statements during the class period, failing to disclose that the projected book-to-bill ratio for Q4 2025 was overstated, which could lead to broader legal repercussions for the company.
- Stock Price Plunge Impact: On February 9, 2026, Medpace reported a book-to-bill ratio of 1.04 for Q4 2025, significantly below the expected 1.15, causing the stock price to drop nearly 16%, reflecting a severe loss of market confidence in the company's future growth prospects.
- Legal Process Explanation: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Medpace stock during the class period can apply to be the lead plaintiff, who will represent all other members in the lawsuit, emphasizing the importance of investor rights in legal proceedings.
See More
Reminder for Medpace Investors on Class Action Lawsuit
- Lawsuit Background: Glancy Prongay Wolke & Rotter LLP reminds investors that June 8, 2026, is the deadline to file a lead plaintiff motion in the class action for those who purchased Medpace stock between April 22, 2025, and February 9, 2026.
- Financial Miss: Medpace's Q4 2025 financial results, released on February 9, 2026, revealed a book-to-bill ratio of 1.04, significantly below the expected 1.15, primarily due to the highest level of backlog cancellations in over a year, resulting in a 15.9% drop in stock price the following day.
- False Statement Allegations: The lawsuit alleges that throughout the class period, Medpace made materially false and misleading statements regarding its business operations and prospects, failing to disclose significant adverse facts that could impact investor decisions.
- Investor Losses: The failure to meet the projected book-to-bill ratio led to substantial losses for investors as the stock price plummeted, with the lawsuit aiming to recover these losses and highlighting the critical importance of transparency and accuracy in investment communications.
See More
Medpace Holdings Faces Class Action Lawsuit Reminder
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Medpace Holdings (NASDAQ:MEDP) for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between April 22, 2025, and February 9, 2026.
- False Statements Allegation: The complaint alleges that Medpace made false and misleading statements during the class period, artificially inflating its share price, which led to investor losses when the truth was revealed, indicating significant misrepresentation by the company.
- Investor Action Call: Affected investors are encouraged to contact the Schall Law Firm before June 5, 2026, to participate in the lawsuit and seek compensation for their losses, highlighting the legal risks that could impact shareholder value.
- Law Firm Background: The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally, demonstrating its expertise and influence in protecting investor rights.
See More
Medpace Faces Class Action for Securities Fraud
- Lawsuit Background: Bleichmar Fonti & Auld LLP has filed a class action against Medpace Holdings Inc. and its executives for securities fraud, leading to significant stock declines and raising serious concerns about the company's financial transparency among investors.
- Stock Price Plunge: On February 9, 2026, Medpace reported a book-to-bill ratio drop to 1.04 due to increased cancellations, causing its stock price to plummet from $530.35 to $446.05, a 15.9% decline, reflecting market disappointment with its performance.
- Ongoing Decline: BFA is investigating reports of rising cancellation rates and a further decline in the book-to-bill ratio, which fell to 0.88 for 1Q 26, indicating increasing operational pressures that could impact future financing capabilities.
- Executive Changes: The resignation of Medpace President Jesse Geiger adds to the uncertainty surrounding the company's governance and future prospects, potentially leading to further erosion of investor confidence.
See More
Medpace Holdings Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Medpace Holdings, aiming to recover damages for investors who purchased securities between April 22, 2025, and February 9, 2026, highlighting serious concerns over the company's financial transparency.
- False Statement Allegations: The complaint alleges that Medpace repeatedly overstated its book-to-bill ratio of 1.15 during earnings calls, despite contrary internal information, which not only harmed investor interests but could also impact the company's future market credibility.
- Investor Participation Opportunity: Affected investors have until June 5, 2026, to request to be appointed as lead plaintiff, indicating the company's commitment to investor rights while providing a legal avenue for potential compensation.
- Legal Fee Arrangement: Bronstein, Gewirtz & Grossman, LLC offers legal services on a contingency fee basis, meaning fees are only collected upon successful recovery, thereby reducing the financial burden on investors and encouraging broader participation in the lawsuit.
See More
Medpace Holdings Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Medpace Holdings (NASDAQ:MEDP) for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between April 22, 2025, and February 9, 2026, with a deadline for participation set for June 5, 2026.
- False Statements Allegation: The complaint alleges that Medpace made false and misleading statements during the class period, artificially inflating its share price, which resulted in investor losses once the truth about the company's performance was revealed, indicating significant misrepresentation in public disclosures.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations for affected investors, encouraging them to discuss their rights, highlighting the firm's specialization in securities class action lawsuits and shareholder rights litigation aimed at helping investors recover losses.
- Lawsuit Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, underscoring the importance of taking action to protect their rights and interests.
See More
Medpace Faces Class Action Lawsuit Allegations
- Class Action Initiation: Robbins Geller law firm announces that investors who purchased Medpace Holdings Inc. stock between April 22, 2025, and February 9, 2026, can seek lead plaintiff status by June 8, 2026, indicating strong investor concern over the company's financial transparency.
- Financial Misrepresentation Allegations: The lawsuit alleges that Medpace and its executives made false or misleading statements during the class period, failing to disclose that the projected book-to-bill ratio for Q4 2025 was overstated, which could lead to broader legal repercussions for the company.
- Stock Price Plunge Impact: On February 9, 2026, Medpace reported a book-to-bill ratio of 1.04 for Q4 2025, significantly below the expected 1.15, causing the stock price to drop nearly 16%, reflecting a severe loss of market confidence in the company's future growth prospects.
- Legal Process Explanation: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Medpace stock during the class period can apply to be the lead plaintiff, who will represent all other members in the lawsuit, emphasizing the importance of investor rights in legal proceedings.
See More
Reminder for Medpace Investors on Class Action Lawsuit
- Lawsuit Background: Glancy Prongay Wolke & Rotter LLP reminds investors that June 8, 2026, is the deadline to file a lead plaintiff motion in the class action for those who purchased Medpace stock between April 22, 2025, and February 9, 2026.
- Financial Miss: Medpace's Q4 2025 financial results, released on February 9, 2026, revealed a book-to-bill ratio of 1.04, significantly below the expected 1.15, primarily due to the highest level of backlog cancellations in over a year, resulting in a 15.9% drop in stock price the following day.
- False Statement Allegations: The lawsuit alleges that throughout the class period, Medpace made materially false and misleading statements regarding its business operations and prospects, failing to disclose significant adverse facts that could impact investor decisions.
- Investor Losses: The failure to meet the projected book-to-bill ratio led to substantial losses for investors as the stock price plummeted, with the lawsuit aiming to recover these losses and highlighting the critical importance of transparency and accuracy in investment communications.
See More
